Oren Livnat
Stock Analyst at HC Wainwright & Co.
(2.15)
# 1,464
Out of 4,479 analysts
109
Total ratings
33.62%
Success rate
-2.55%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Maintains: Buy | $87 → $94 | $63.03 | +49.15% | 8 | Jun 26, 2024 | |
| CARA Cara Therapeutics | Downgrades: Neutral | n/a | $0.28 | - | 10 | Jun 13, 2024 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $6 | $2.07 | +190.56% | 8 | May 31, 2024 | |
| VRCA Verrica Pharmaceuticals | Maintains: Buy | $13 → $14 | $7.83 | +78.80% | 9 | May 14, 2024 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $57 → $61 | $27.50 | +121.82% | 8 | May 13, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Buy | $25 → $27 | $13.98 | +93.20% | 10 | May 9, 2024 | |
| PCRX Pacira BioSciences | Reiterates: Buy | $57 | $22.40 | +154.46% | 14 | May 8, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Buy | $200 | $105.27 | +90.00% | 13 | May 3, 2024 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $15 | $4.36 | +244.43% | 3 | Apr 3, 2024 | |
| MNKD MannKind | Reiterates: Buy | $7.5 | $4.98 | +50.60% | 6 | Jan 4, 2024 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | n/a | $32.46 | - | 4 | Aug 4, 2023 | |
| AGRX Agile Therapeutics | Reiterates: Buy | $12 | $1.42 | +745.07% | 8 | Jun 26, 2023 | |
| ACST Acasti Pharma | Initiates: Buy | $14 | $2.87 | +402.44% | 1 | Dec 15, 2022 | |
| SCYX SCYNEXIS | Maintains: Buy | $14 → $8 | $1.98 | +305.06% | 2 | May 13, 2022 | |
| LPCN Lipocine | Maintains: Buy | n/a | $7.69 | - | 3 | Aug 26, 2021 | |
| VYNE VYNE Therapeutics | Maintains: Buy | n/a | $1.90 | - | 2 | May 7, 2021 |
ANI Pharmaceuticals
Jun 26, 2024
Maintains: Buy
Price Target: $87 → $94
Current: $63.03
Upside: +49.15%
Cara Therapeutics
Jun 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.28
Upside: -
Xeris Biopharma Holdings
May 31, 2024
Reiterates: Buy
Price Target: $6
Current: $2.07
Upside: +190.56%
Verrica Pharmaceuticals
May 14, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $7.83
Upside: +78.80%
Tarsus Pharmaceuticals
May 13, 2024
Maintains: Buy
Price Target: $57 → $61
Current: $27.50
Upside: +121.82%
Avadel Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $25 → $27
Current: $13.98
Upside: +93.20%
Pacira BioSciences
May 8, 2024
Reiterates: Buy
Price Target: $57
Current: $22.40
Upside: +154.46%
Jazz Pharmaceuticals
May 3, 2024
Reiterates: Buy
Price Target: $200
Current: $105.27
Upside: +90.00%
Zevra Therapeutics
Apr 3, 2024
Reiterates: Buy
Price Target: $15
Current: $4.36
Upside: +244.43%
MannKind
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $4.98
Upside: +50.60%
Collegium Pharmaceutical
Aug 4, 2023
Reiterates: Neutral
Price Target: n/a
Current: $32.46
Upside: -
Agile Therapeutics
Jun 26, 2023
Reiterates: Buy
Price Target: $12
Current: $1.42
Upside: +745.07%
Acasti Pharma
Dec 15, 2022
Initiates: Buy
Price Target: $14
Current: $2.87
Upside: +402.44%
SCYNEXIS
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $1.98
Upside: +305.06%
Lipocine
Aug 26, 2021
Maintains: Buy
Price Target: n/a
Current: $7.69
Upside: -
VYNE Therapeutics
May 7, 2021
Maintains: Buy
Price Target: n/a
Current: $1.90
Upside: -